AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00795678
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
Trial: NCT00795678
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
Trial: NCT00795678
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
Trial: NCT01947855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching Empagliflozin low dose
Trial: NCT01947855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching Empagliflozin high dose
Trial: NCT03225313
Drug: Normal Saline Flush, 0.9% Injectable Solution_#5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injected into rectus sheath using ultrasound \& locally surrounding the hernia
Trial: NCT00883129
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
Trial: NCT00883129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
Trial: NCT01477775
Drug: Oral P2Y12 receptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free choice among clopidogrel, prasugrel or ticagrelor
Trial: NCT01477775
Drug: Customized choice for the oral P2Y12 receptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
Trial: NCT02831478
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied liberally to the skin (Formulation: RB# Z16-071)
Trial: NCT01898884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04583592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
Trial: NCT02983773
Drug: THC 3.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 smoked marijuana cigarette with 3.0% THC
Trial: NCT02983773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 smoked placebo marijuana cigarette
Trial: NCT03894007
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
Trial: NCT02255435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03161379
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Trial: NCT01343641
Drug: MK-0677
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
Trial: NCT01343641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Pill used as a comparator
Trial: NCT01934647
Drug: MK-8892
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
Trial: NCT03930264
Drug: Azathioprine 50Mg Tab
RxNorm normalized name: AZATHIOPRINE 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03930264
Drug: Azathioprine 10mg/mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT01638442
Drug: CHR-2797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
Trial: NCT01638442
Drug: CHR-2797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------
Trial: NCT04249232
Drug: Placebo prefilled injector pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prefilled injector pen to deliver inactive solution daily subcutaneously
Trial: NCT03830905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo once a day during 3 days
Trial: NCT01588418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered in random order 30 min before OGTT-PET study in the same subject
Trial: NCT03607513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to JNJ-64264681 will be administered as oral solution.
Trial: NCT01012219
Drug: Comparator: aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg oral tablet once daily for 7 days
Trial: NCT01012219
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablet once daily for 7 days
Trial: NCT01710137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02263352
Drug: Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 8mgms taken orally ,one per day for two months.
Trial: NCT01206322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The acute effects of intranasal sterile saline.
Trial: NCT01250496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Trial: NCT01542567
Drug: Abitren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
Trial: NCT01542567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories
Trial: NCT03935568
Drug: PU-AD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 cohorts receiving a single oral dose of PU-AD at one time.
Trial: NCT03935568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cohorts receiving a single oral dose of Placebo at one time
Trial: NCT03935568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cohorts receiving multiple oral dose of Placebo at one time
Trial: NCT03935568
Drug: PU-AD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 cohorts receiving multiple oral dose of PU-AD at one time
Trial: NCT01697410
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Trial: NCT00205270
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly each season
Trial: NCT01863160
Drug: 0.1% ZEP-3 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream
Trial: NCT00027573
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00027573
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01262274
Drug: Anastrozole plus tegafur-uracil
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
Trial: NCT01788813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
Trial: NCT00544349
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01371006
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz single dosing once daily
Trial: NCT01371006
Drug: normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz once daily
Trial: NCT01371006
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz single dosing once daily
Trial: NCT00503035
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg by mouth twice daily x 6 months
Trial: NCT01680198
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02936661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00522925
Drug: PS433540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg capsule, once daily for 28 days
Trial: NCT00522925
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule, once daily for 28 days
Trial: NCT00522925
Drug: PS433540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg capsule, once daily for 28 days
Trial: NCT03530007
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline used for prevention of spinal shivering
Trial: NCT03963167
Drug: BDP/FF/G fixed combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
Trial: NCT04527159
Drug: Fluoraphat Pro / VivaSens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desensitizing agents for treatment of dentinal hypersensitivity
Trial: NCT02216214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04495296
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered by specified doses on specified day
Trial: NCT03264118
Drug: Toluidine Blue O
RxNorm normalized name: Toluidine Blue O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
Trial: NCT02826174
Drug: Anti-Rejection Agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Rejection Agents for both groups
Trial: NCT02826174
Drug: Anti-Inflammatory Agents
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Inflammatory Agents for both groups
Trial: NCT01757873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01598740
Drug: CLP
RxNorm normalized name: Endopeptidase Clp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01598740
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02992808
Drug: HP-HMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01317550
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth twice a day for a 10 week cycle.
Trial: NCT03504956
Drug: Contrast
RxNorm normalized name: CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
Trial: NCT03504956
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
Trial: NCT00442572
Drug: PEGASYS [peginterferon alfa-2a]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
Trial: NCT04044690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
Trial: NCT04501861
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Trial: NCT01987570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790972
Drug: Sinofresh
RxNorm normalized name: MENTHA PIPERITA 3 [hp_X] in 100 mL ORAL SPRAY [ANTISEPTIC SINOFRESH KOOL BLAST THROAT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two sprays in each nostril three times daily for one week
Trial: NCT00790972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two sprays in each nostril three times daily for one week
Trial: NCT03095196
Drug: HF drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: full medical therapy to treat HF symptoms and its progression.
Trial: NCT00125125
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00812045
Drug: AZD1236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 75 mg twice daily during 4 weeks
Trial: NCT00812045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00154089
Drug: EM-1421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
Trial: NCT01649999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01588678
Drug: DS-3078a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
Trial: NCT03952377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal Epidural Injection
Trial: NCT01676636
Drug: Unflavoured Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
Trial: NCT01676636
Drug: Flavoured Powder
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
Trial: NCT00891540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic NaCl
Trial: NCT04958460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
Trial: NCT01466829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; saline injection.
Trial: NCT00004913
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004913
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00557700
Drug: Administration of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo
Trial: NCT03294382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
Trial: NCT04509440
Drug: corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
Trial: NCT03813160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02448212
Drug: TS-121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02448212
Drug: [11C]TASP0410699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous radiotracer
Trial: NCT02205489
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT00155675
Drug: GUSUIBU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03236324
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
Trial: NCT02366091
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
Trial: NCT02366091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
Trial: NCT02164084
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel with hydrogel
Trial: NCT02511873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily